date:Aug 18, 2014
t targets, and will allow for scalability, which is difficult via the leaf.
Neil Goldsmith, Evolva CEO, commented, This breakthrough will allow consumers all over the world to enjoy products using Reb M at a commercially viable price. This patent application forms part of our ever-expanding IP portfolio on steviol glycosides, which we are confident is the most extensive, and the most commercially significant in this space.
David Henstrom, Vice President for Health Ingredients, Cargill, added: